Analysts Set Benitec Biopharma Limited (NASDAQ:BNTC) Target Price at $24.00

by · The Cerbat Gem

Shares of Benitec Biopharma Limited (NASDAQ:BNTC – Get Free Report) have been assigned an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $24.00.

Several equities analysts recently commented on the company. Wedbush upped their target price on Benitec Biopharma from $16.00 to $17.00 and gave the company an “outperform” rating in a research note on Tuesday. Royal Bank Of Canada raised Benitec Biopharma to an “outperform” rating in a research note on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Benitec Biopharma in a report on Friday, July 17th. Citigroup reaffirmed a “market outperform” rating on shares of Benitec Biopharma in a research note on Tuesday. Finally, Wall Street Zen lowered shares of Benitec Biopharma from a “hold” rating to a “sell” rating in a report on Saturday.

View Our Latest Stock Analysis on BNTC

Benitec Biopharma Stock Performance

BNTC stock opened at $11.02 on Wednesday. The stock has a market capitalization of $384.38 million, a P/E ratio of -11.24 and a beta of 0.27. Benitec Biopharma has a one year low of $9.85 and a one year high of $16.76. The company has a 50 day moving average price of $12.43 and a two-hundred day moving average price of $12.03.

Benitec Biopharma (NASDAQ:BNTC – Get Free Report) last issued its quarterly earnings results on Monday, September 14th. The biotechnology company reported ($0.26) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.26). Research analysts forecast that Benitec Biopharma will post -1.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Benitec Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of BNTC. AWM Investment Company Inc. purchased a new position in Benitec Biopharma during the second quarter worth approximately $2,515,000. Bank of New York Mellon Corp purchased a new stake in shares of Benitec Biopharma during the 2nd quarter valued at $804,000. GAMMA Investing LLC grew its stake in shares of Benitec Biopharma by 18.7% during the 2nd quarter. GAMMA Investing LLC now owns 7,961 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 1,256 shares during the period. Bank of America Corp DE grew its stake in shares of Benitec Biopharma by 43.3% during the 1st quarter. Bank of America Corp DE now owns 17,376 shares of the biotechnology company’s stock valued at $185,000 after buying an additional 5,251 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Benitec Biopharma during the 1st quarter worth $186,000. Institutional investors and hedge funds own 52.19% of the company’s stock.

Benitec Biopharma Company Profile

(Get Free Report)

Benitec Biopharma Inc (NASDAQ:BNTC) is a clinical-stage biotechnology company developing genetic medicines based on DNA-directed RNA interference (ddRNAi). The company’s technology is designed to enable long-lasting suppression of disease-causing genes by delivering genetic instructions that produce RNA interference molecules within targeted cells.

Benitec’s lead product candidate is BB-301, an investigational gene therapy being developed for oculopharyngeal muscular dystrophy type 1 (OPMD), a rare inherited disorder that can cause progressive weakness of the muscles involved in swallowing and eye movement.

Featured Stories